CORT — CORCEPT THERAPEUTICS INC catalysts
Next verified catalyst
2026-12-01 — Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With C · official source ↗
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patie
Phase 2 · Cushing Syndrome |
CORT CORCEPT THERAPEUTICS INC | relacorilant |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|